ECONOMIC EVALUATION OF RAMUCIRUMAB AS SECOND-LINE CHEMOTHERAPY FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA IN CHINA

被引：0
|
作者：
Luo, X. [1 ]
Peng, L. [1 ]
Tan, C. [1 ]
Wan, X. [1 ]
Zeng, X. [1 ]
机构：
[1] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.216
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN139
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Ramucirumab plus paclitaxel as a second-line treatment for advanced gastric or gastro-oesophageal junction cancer
    [J]. Nature Reviews Gastroenterology & Hepatology, 2014, 11 (11) : 642 - 642
  • [2] Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
    Young, Kate
    Smyth, Elizabeth
    Chau, Ian
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2015, 8 (06): : 373 - 383
  • [3] Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
    Li, Sini
    Peng, Liubao
    Tan, Chongqing
    Zeng, Xiaohui
    Wan, Xiaomin
    Luo, Xia
    Yi, Lidan
    Li, Jianhe
    [J]. PLOS ONE, 2020, 15 (05):
  • [4] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Buyukkaramikli, Nasuh C.
    Blommestein, Hedwig M.
    Riemsma, Rob
    Armstrong, Nigel
    Clay, Fiona J.
    Ross, Janine
    Worthy, Gill
    Severens, Johan
    Kleijnen, Jos
    Al, Maiwenn J.
    [J]. PHARMACOECONOMICS, 2017, 35 (12) : 1211 - 1221
  • [5] Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Nasuh C. Büyükkaramikli
    Hedwig M. Blommestein
    Rob Riemsma
    Nigel Armstrong
    Fiona. J. Clay
    Janine Ross
    Gill Worthy
    Johan Severens
    Jos Kleijnen
    Maiwenn J. Al
    [J]. PharmacoEconomics, 2017, 35 : 1211 - 1221
  • [6] Second and third-line palliative chemotherapy for advanced gastro-oesophageal adenocarcinoma
    Lavery, Anita
    Hamilton, Ashleigh
    Taylor, Kirsty
    Ddamba, James
    McCarthy, Aisling
    Park, Richard
    Harte, Robert
    Harrison, Claire
    Purcell, Colin
    Eatock, Martin
    Turkington, Richard
    [J]. BRITISH JOURNAL OF SURGERY, 2017, 104 : 11 - 11
  • [7] Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
    Fuchs, Charles S.
    Tomasek, Jiri
    Yong, Cho Jae
    Dumitru, Filip
    Passalacqua, Rodolfo
    Goswami, Chanchal
    Safran, Howard
    dos Santos, Lucas Vieira
    Aprile, Giuseppe
    Ferry, David R.
    Melichar, Bohuslav
    Tehfe, Mustapha
    Topuzov, Eldar
    Zalcberg, John Raymond
    Chau, Ian
    Campbell, William
    Sivanandan, Choondal
    Pikiel, Joanna
    Koshiji, Minori
    Hsu, Yanzhi
    Liepa, Astra M.
    Gao, Ling
    Schwartz, Jonathan D.
    Tabernero, Josep
    [J]. LANCET, 2014, 383 (9911): : 31 - 39
  • [8] IMPACT OF MODEL APPROACH ON ECONOMIC EVALUATION OF NIVOLUMAB PLUS CHEMOTHERAPY FOR ADVANCED GASTRIC, GASTRO-OESOPHAGEAL JUNCTION AND OESOPHAGEAL CANCER
    Young, R.
    Padgett, K.
    Brown, T.
    Okorogheye, G.
    Jones, B.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S119 - S119
  • [9] Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
    Zeng, Hanqing
    Wang, Chunjiang
    Song, Li-Ying
    Jia, Su-Jie
    Zeng, Xiaohui
    Liu, Qiao
    [J]. BMJ OPEN, 2022, 12 (11):
  • [10] PACLITAXEL AS SECOND-LINE CHEMOTHERAPY IN ADVANCED OR RECURRENT GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
    Machado, Karime
    Toloi, Diego
    Nebuloni, Daniela
    Ribeiro, Suilane
    Riechelmann, Rachel
    Fukushima, Julia
    Freitas, Helano
    Hoff, Paulo
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v48 - v49
12345